Shire plc : Block listing Interim Review BLOCK LISTING

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
26
Shire plc : Block listing Interim Review

BLOCK LISTING SIX MONTHLY RETURN

November 24, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)

Name of applicant : Shire plc
Name of scheme: Shire Sharesave Scheme
Period of return: From: May 23, 2017 To:  November 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 167,532
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 4,012
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 163,520

  

Name of applicant : Shire plc
Name of scheme: Shire Portfolio Share Plan
Period of return: From: May 23, 2017 To: November 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 360,742
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 90,208
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 270,534
Name of applicant : Shire plc
Name of scheme: Shire Employee Stock Purchase Plan
Period of return: From: May 23, 2017 To: November 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 237,698
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): Nil
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 237,698
Name of applicant : Shire plc
Name of scheme: Shire Long Term Incentive Plan 2015
Period of return: From: May 23, 2017 To: November 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 2,687,072
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 188,501
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 2,498,571
Name of applicant : Shire plc
Name of scheme: Shire Global Employee Stock Purchase Plan
Period of return: From: May 23, 2017 To: November 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 1,600,843
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 800,060
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 800,783
Name of applicant : Shire plc
Name of scheme: Baxalta Exchange Awards
Period of return: From: May 23, 2017 To: November 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 17,995,867
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 765,528
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 17,230,339
Name of applicant : Shire plc
Name of scheme: Combined block listing in respect of the Shire Portfolio Share Plan, the Shire Long Term Incentive Plan 2015 and the Shire Global Employee Stock Purchase Plan.
Period of return: From: July 7, 2017 To: November 22, 2017
Balance of unallotted securities under scheme(s) from previous return: N/A
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 3,000,000
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): Shire Portfolio Share Plan: Nil Shire Long Term Incentive Plan 2015: Nil Shire Global Employee Stock Purchase Plan: Nil
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 3,000,000

Amendment of Block listing six monthly return released May 23, 2017:

November 24, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the Block listing six monthly return released May 23, 2017, has been amended to reflect the following:

The number of securities issued/allotted under the Shire Portfolio Share Plan is amended from 405,083 to 408,873 and the balance not yet issued/allotted under this scheme is amended from 364,532 to 360,742.

The number of securities issued/allotted under the Shire Long Term Incentive Plan 2015 is amended from 145,740 to 149,340 and the balance not yet issued/allotted under this scheme is amended from 2,690,672 to 2,687,072.

The full amended announcement is below.

May 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)

Name of applicant : Shire plc
Name of scheme: Shire Sharesave Scheme
Period of return: From: November 23, 2016 To:  May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 184,611
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 17,079
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 167,532

  

Name of applicant : Shire plc
Name of scheme: Shire Portfolio Share Plan
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 769,615
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 408,873
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 360,742

  

Name of applicant : Shire plc
Name of scheme: Shire Employee Stock Purchase Plan
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 244,057
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 6,359
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 237,698
Name of applicant : Shire plc
Name of scheme: Shire Long Term Incentive Plan 2015
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 2,836,412
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 149,340
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 2,687,072
Name of applicant : Shire plc
Name of scheme: Shire Global Employee Stock Purchase Plan
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 1,604,243
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 3,400
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 1,600,843
Name of applicant : Shire plc
Name of scheme: Baxalta Exchange Awards
Period of return: From: November 23, 2016 To: May 22, 2017
Balance of unallotted securities under scheme(s) from previous return: 20,488,204
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Nil
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 2,492,337
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 17,995,867
Name of contact: Sarah Rixon, Company Secretarial Assistant
Telephone number of contact: 01256 894000

For further information please contact:

Investor Relations    
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 203 549 0874
Media    
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Katie Joyce kjoyce@shire.com   +1 781 482 2779

NOTES TO EDITORS

About Shire

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people's lives with medicines that have a meaningful impact on patients and all who support them on their journey.

www.shire.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 4

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading

Top 5 Most Recently Viewed Articles

Celcuity Inc. Prepares for Third Quarter Financial Results

Updated Category News Views 91

Celcuity Inc. Announces Upcoming Financial Results Release Celcuity Inc. (NASDAQ: CELC), a pioneering biotechnology company focused on innovative oncology therapies, has exciting news. The company will be releasing its financial results for the third quarter of 2025 after the market closes. This significant event is scheduled for a Wednesday, with management set to...

Continue Reading
EverTrue and DonorSearch Team Up to Revolutionize Fundraising

Updated Category News Views 973

EverTrue's Strategic Acquisition of DonorSearch EverTrue, a leader in donor engagement and pipeline development, recently announced a significant acquisition. The company has acquired DonorSearch, known for its innovative AI-powered donor discovery solutions. This strategic move is aimed at enhancing the capabilities of fundraising teams, enabling them to connect with...

Continue Reading
Celebrating Creativity and Inclusion: ADCOLOR Awards 2025

Updated Category News Views 315

ADCOLOR Awards 2025: A Night of Inspiration and Celebration Presented by leading organizations in the industry like Amazon, Disney, and Meta, the ADCOLOR Awards is a prestigious event celebrating remarkable individuals and organizations that champion diversity and inclusion in creative fields. This year's ceremony showcased inspiring figures such as Richelieu Dennis,...

Continue Reading
Transforming a $1000 Investment in First Solar to $3700

Updated Category News Views 161

Transform Your Investment with First Solar First Solar (NASDAQ: FSLR) has shown impressive performance over the past decade. This company has not only managed to keep pace with the market but has actually outperformed it by an average of 2.49% annually. This impressive annualized return translates to an average annual growth of 14.22%, making First Solar a notable player...

Continue Reading
Carpenter Technology Announces New Quarterly Dividend Plans

Updated Category News Views 107

Carpenter Technology Announces Quarterly Cash Dividend Carpenter Technology Corporation (NYSE: CRS), a leading name in high-performance specialty alloys, has made a significant announcement regarding its quarterly cash dividend. The company's Board of Directors has declared a dividend of $0.20 per share on common stock, underscoring its commitment to returning value to...

Continue Reading